1,25(OH)2D3 Promotes the Efficacy of CD28 Costimulation Blockade by Abatacept by Gardner, David et al.
 
 
University of Birmingham
1,25(OH)2D3 Promotes the Efficacy of CD28
Costimulation Blockade by Abatacept
Gardner, David; Jeffery, Louisa; Soskic, Blagoje; Briggs, Zoe; Hou, Tie Zheng; Raza, Karim;
Sansom, David
DOI:
10.4049/jimmunol.1500306
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Gardner, D, Jeffery, L, Soskic, B, Briggs, Z, Hou, TZ, Raza, K & Sansom, D 2015, '1,25(OH)2D3 Promotes the
Efficacy of CD28 Costimulation Blockade by Abatacept', Journal of Immunology, vol. 195, no. 6, pp. 2657-2665.
https://doi.org/10.4049/jimmunol.1500306
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
This is an open-access article distributed under the terms of the CC-BY 3.0 Unported license.
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
of September 22, 2015.
This information is current as
Costimulation Blockade by Abatacept
 Promotes the Efficacy of CD283D21,25(OH)
Briggs, Tie Zheng Hou, Karim Raza and David M. Sansom
David H. Gardner, Louisa E. Jeffery, Blagoje Soskic, Zoe
http://www.jimmunol.org/content/195/6/2657
doi: 10.4049/jimmunol.1500306
August 2015;
2015; 195:2657-2665; Prepublished online 14J Immunol 
Material
Supplementary
6.DCSupplemental.html
http://www.jimmunol.org/content/suppl/2015/08/14/jimmunol.150030
References
http://www.jimmunol.org/content/195/6/2657.full#ref-list-1
, 27 of which you can access for free at: cites 59 articlesThis article 
Subscriptions
http://jimmunol.org/subscriptions
 is online at: The Journal of ImmunologyInformation about subscribing to 
Permissions
http://www.aai.org/ji/copyright.html
Submit copyright permission requests at: 
Email Alerts
http://jimmunol.org/cgi/alerts/etoc
Receive free email-alerts when new articles cite this article. Sign up at: 
Print ISSN: 0022-1767 Online ISSN: 1550-6606. 
Copyright © 2015 The Authors All rights reserved.
9650 Rockville Pike, Bethesda, MD 20814-3994.
The American Association of Immunologists, Inc.,
 is published twice each month byThe Journal of Immunology
 at U
niversity of Birm
ingham
 on Septem
ber 22, 2015
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
 at U
niversity of Birm
ingham
 on Septem
ber 22, 2015
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
The Journal of Immunology
1,25(OH)2D3 Promotes the Efficacy of CD28 Costimulation
Blockade by Abatacept
David H. Gardner,* Louisa E. Jeffery,* Blagoje Soskic,† Zoe Briggs,* Tie Zheng Hou,†
Karim Raza,*,‡,1 and David M. Sansom†,1
Inhibition of the CD28:CD80/CD86 T cell costimulatory pathway has emerged as an effective strategy for the treatment of T cell–
mediated inflammatory diseases. However, patient responses to CD28-ligand blockade by abatacept (CTLA-4-Ig) in conditions
such as rheumatoid arthritis are variable and often suboptimal. In this study, we show that the extent to which abatacept
suppresses T cell activation is influenced by the strength of TCR stimulation, with high-strength TCR stimulation being associated
with relative abatacept insensitivity. Accordingly, cyclosporin A, an inhibitor of T cell stimulation via the TCR, synergized with
abatacept to inhibit T cell activation. We also observed that 1,25-dihydroxyvitamin D3 enhanced the inhibition of T cell activation
by abatacept, strongly inhibiting T cell activation driven by cross-linked anti-CD3, but with no effect upon anti-CD28 driven
stimulation. Thus, like cyclosporin A, 1,25-dihydroxyvitamin D3 inhibits TCR-driven activation, thereby promoting abatacept sen-
sitivity. Vitamin D3 supplementation may therefore be a useful adjunct for the treatment of conditions such as rheumatoid arthri-
tis in combination with abatacept to promote the efficacy of treatment. The Journal of Immunology, 2015, 195: 2657–2665.
C
D4+ T cell effector responses are generated following the
integration of signals derived from APCs. The specificity
of these responses is determined by activation of the TCR
by specific peptide fragments presented by MHC II (1). In addition,
costimulatory pathways deliver signals that enhance T cell activa-
tion and guide differentiation (2). The initial source of costimulation
is via CD28, a T cell surface protein that is constitutively expressed
by resting CD4+ T cells. CD28 interacts with CD80 and CD86, both
of which are upregulated by APCs in response to inflammation.
These interactions with CD28 reduce T cell activation thresholds
(3), promote effector T cell survival (4), and enhance cytokine ex-
pression (5). CD28 costimulation is therefore widely viewed as an
essential requirement for T cell activation and a control point that
can be targeted therapeutically.
The extent of CD28 signaling is influenced by the expression of
CTLA-4 on both regulatory T cells (Treg) and activated T cells.
CTLA-4 binds to CD80 and CD86 with higher affinity than CD28
(6) and can therefore outcompete CD28 for ligand binding. These
interactions result in the removal of CD80 and CD86 from APCs by
CTLA-4 via trans-endocytosis (7). Consequently, whereas inter-
actions between CD80 or CD86 and CD28 result in T cell costimu-
lation, interactions with CTLA-4 inhibit T cell activation (8). The
importance of CTLA-4 regulation is emphasized by the lethal
lymphoproliferative disorder seen in CTLA-42/2mice (9, 10). This
loss of immune regulation in the absence of CTLA-4 appears to be
driven byCD28because the interruption ofCD28 signaling prevents
disease (11).
The regulatory function of CTLA-4 has been harnessed in a
clinical setting for the treatment of T cell–mediated inflammatory
diseases, through the use of the CTLA-4-Ig fusion protein. The
efficacy of this approach has been validated in animal models of
collagen-induced arthritis, systemic lupus erythematosus, auto-
immune diabetes, experimental autoimmune encephalomyelitis,
and organ transplantation models (12). Several clinical trials have
also demonstrated CTLA-4-Ig (abatacept) to be effective in the
treatment of rheumatoid arthritis; however, a significant propor-
tion of patients displays a limited clinical response (13).
There are several plausible explanations for a lack of efficacy of
abatacept in subgroups of patients. For example, the timing of co-
stimulation blockade may not overlap with a time frame in which
T cell activation is relevant in the disease setting. Alternatively, as
seen in some animal models (14, 15), T cell effector responses may
not always require CD28 costimulation, and other T cell stimulatory
pathways may be able to compensate for its absence. Finally, aba-
tacept may not be effective in blocking CD28 costimulation in all
settings; this view led to the development of a variant CTLA-4-Ig
(belatacept) that binds to CD80/CD86 with higher affinity (16) and
that has been used in renal transplantation (17). However, the higher
affinity of belatacept may increase the risk of adverse events, in-
cluding acute rejection, and could impact Treg homeostasis (18). An
alternative approach to using increased affinity analogs would be
to understand the limitations of abatacept, such as conditions
under which T cells become costimulation independent, to in-
crease its potency through use in combination with other agents.
In this study, we show that the level of abatacept sensitivity is
inversely associated with the strength of TCR signaling. In addi-
tion we found that 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] acts
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directly upon T cells to inhibit their activation driven by the TCR in
the absence of costimulation. Thus, by increasing reliance on CD28
costimulation, 1,25(OH)2D3 renders T cell responses more abatacept
sensitive. These data suggest that vitamin D3 supplementation may
be a simple approach to improve outcomes of abatacept treatment in
patients with T cell–mediated inflammatory diseases.
Materials and Methods
Cell culture
Chinese hamster ovary (CHO) cells were cultured in DMEM (Life Tech-
nologies, Paisley, U.K.) supplementedwith 10%v/v FBS (Biosera, Uckfield,
U.K.), 50 U/ml penicillin and streptomycin (Life Technologies), and 200 mM
L-glutamine (Life Technologies) and incubated at 37˚C in a humidified at-
mosphere of 5% CO2. CHO cell lines expressing CD80, CD86, FcRgII
(CD32; FcR), or FcR/CD80 were generated, as previously described (7).
Cell isolation
PBMCs were isolated from leukocyte reduction system cones (National Blood
Service, Birmingham, U.K.) by Ficoll density gradient centrifugation. CD4+
CD252 T cells were purified using an EasySep negative selection Ab mixture
(StemCell Technologies), according to manufacturer’s instructions. Primary
human monocytes were purified from PBMCs using an EasySep monocyte
enrichment mixture (StemCell Technologies). For monocyte-derived den-
dritic cell (DC) differentiation, monocytes were cultured in the presence
of GM-CSF (800 U/ml; Berlex Laboratories, Richmond, CA) and IL-4
(500 U/ml; Miltenyi Biotec, Bisley, U.K.) for 7 d.
CD4+CD252 T cell stimulation
Atotal of13105Tcellswascoculturedwitheither23104allogeneicDCsor
glutaraldehyde-fixed CHO cells in 96-well plates for 5 d (unless otherwise
stated) in RPMI 1640 supplemented with 10% FBS, 50 U/ml penicillin and
streptomycin, and 200mML-glutamine. Stimulations were treated with anti-
CD3 (OKT3; 500 ng/ml, unless otherwise stated), anti-CD28 (9.3; 500 ng/ml),
or toxic shock syndrome toxin (TSST)-1 at indicated concentrations
(Toxin Technology, Sarasota, FL). Alternatively, T cells were stimulated for
5 d with Dynabeads Human T-Activator CD3/CD28 beads (Life Technolo-
gies). Where indicated, stimulations were treated with abatacept (20 mg/ml;
Bristol Myers Squibb), 1,25(OH)2D3 (10 nM; Sigma-Aldrich), or cyclo-
sporinA (CsA; Sigma-Aldrich). The concentrationof 1,25(OH)2D3 usedwas
determined from previous experience (19) and similar to those used by others
(20, 21). The vehicle for 1,25(OH)2D3 was ethanol, which was diluted to
a final concentration of 0.01% (v/v) during experiments; vehicle controls
showed no effect upon experimental outcomes. PBS vehicle was used for
all other reagents.
Flow cytometry
The following Abs were used: anti-CD25 (2A3) conjugated to FITC; anti–
CTLA-4 (BNI3), anti-ICOS (DX29), anti-OX40 (ACT35), and anti-STAT5
(pY694) conjugated to PE; anti–PD-1 (MIH4), anti-CD28 (CD28.2), anti-
CD62L (DREG-56), and anti-CD71 (M-A712) conjugated to allophyco-
cyanin (all from BD Biosciences); anti-FOXP3 (PCH101) conjugated
to allophycocyanin (eBioscience); and anti-TCR vb2 conjugated to PE
(Beckman Coulter Immunotech, Marseille, France). For analysis of cell
surface proteins, cells were recovered following stimulation, washed once by
centrifugation in PBS, and incubated with relevant Abs in PBS supplemented
with 2% (v/v) goat serum (Sigma-Aldrich) for 30 min at 4˚C. A FOXP3
stainingbuffer kit (eBioscience)was used for intracellular stainingof FOXP3
and CTLA-4 in accordance with manufacturer’s instructions. Staining for
pSTAT5 was performed using a BD Phosflow buffer kit (BD Biosciences).
For the detectionof cytokine expression,T cellswere stimulated for 5 d under
indicated conditions and then restimulated for 4 h with 50 ng/ml PMA
(Sigma-Aldrich) and 1mMionomycin (Sigma-Aldrich) in the presence of 10
mg/ml brefeldin A (Sigma-Aldrich). Cells were then washed with PBS and
fixed with 3% (w/v) paraformaldehyde in PBS for 12 min at room temper-
ature. Subsequently, cells were permeabilized with 0.1% (w/v) saponin in
PBSand stained at room temperature for 30min.All datawere acquiredusing
a CyAn ADP Flow Cytometer (DakoCytomation, Ely, U.K.) and were ana-
lyzed using FlowJo software (Tree Star, Ashland, OR).
CD4+ T cell proliferation assays
Prior to stimulation, CD4+CD252 T cells were labeled with CellTrace Vio-
let (Life Technologies). Following stimulation, T cell proliferation was
FIGURE 1. Efficacy of CD28 blockade by abatacept is dependent upon
strength of TCR stimulation. (A) CellTrace Violet–labeled CD4+CD252
T cells were incubated with 500 ng/ml anti-CD3 and either CHO-CD80,
CHO-CD86, or anti-CD3/anti-CD28–coated beads and with or without
20 mg/ml abatacept (bold line) for 5 d, followed by flow cytometric analysis
of CellTrace Violet dilution. Flow cytometry data from one representative
experiment of more than five performed. (B) CellTrace Violet–labeled
T cells were stimulated with indicated anti-CD3 concentrations and
DCs for 5 d. Representative flow cytometry data and combined data from
independent experiments are shown (n = 8) expressed as mean 6 SE
for division index values and total number of proliferating CellTrace
Violetlow T cells. (C) CellTrace Violet–labeled T cells were stimulated
with DCs and 500 ng/ml anti-CD3 for 5 d and were treated with indicated
CsA concentrations, 20 mg/ml abatacept, or both. Representative flow
cytometry data and mean division index 6 SE values from independent
experiments (n = 7). *p # 0.05, **p # 0.01, ***p # 0.001, two-tailed
paired t test. ns, not significant.
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analyzed by flow cytometry. Proliferation profiles were modeled using the
Flowjo proliferation platform to determine the division index, which repre-
sents the average number of cell divisions undergone by a T cell in the
original population.
Detection of T cell apoptosis
Following 5-d incubation, T cell apoptosis was determined by analysis of
mitochondrial depolarization, a marker of early apoptosis (22). Cells were
washed and incubated with 23 ng/ml 3,39-dihexyloxacarbocyanine iodide
(DiOC6; Molecular Probes, Eugene, OR) for 20 min at 37˚C. Cells were
analyzed by flow cytometry, and apoptotic cells were characterized as a
DiOC6
low population that was verified by forward/side scatter profiles.
Statistics
Statistical analyses were performed using Prism 5.0 software (GraphPad
Software, La Jolla, CA). The p values,0.05 were considered significant.
Results
Efficacy of CD28 costimulation blockade by abatacept is
determined by the quality of TCR stimulation
To test the efficacy of T cell stimulation blockade by abatacept in vitro,
we stimulated CellTrace Violet–labeled CD4+CD252 human T cells
with soluble anti-CD3 and CHO cells expressing either CD80 or
CD86. Treatment with a saturating abatacept concentration (20 mg/ml)
robustly inhibited T cell proliferation driven by either CD80 or
CD86 (Fig. 1A). As predicted, abatacept had no impact upon T cell
proliferation driven by anti-CD3/anti-CD28–coated beads due to
the absence of CD28 ligands in this system (Fig. 1A). These experi-
ments therefore demonstrated the specificity and efficacy of abata-
cept blockade.
Surprisingly, during experiments using ligand-expressing DCs, we
noted that abatacept had a limited impact on T cell proliferation when
CD4+CD252 T cells were stimulated with DCs in conjunction with
the same concentrations of soluble anti-CD3 (500 ng/ml anti-CD3)
that was used with CHO transfectants. However, we found signifi-
cant influence of anti-CD3 concentration on the effect of abatacept
treatment such that, at lower anti-CD3 concentrations (#0.5 ng/ml
anti-CD3), T cell proliferation was strongly inhibited by abatacept
(Fig. 1B). This indicated that the strength of TCR signaling had
a significant effect on abatacept sensitivity.
CsA is a calcineurin inhibitor that acts to prevent NFAT translo-
cation downstream of TCR stimulation (23). Therefore, we stimu-
lated T cells in the presence of CsA to further investigate the impact
of inhibiting the TCR pathway in our experiments. Interestingly,
neither CsA (0.1 mg/ml) nor abatacept (20 mg/ml) alone robustly
inhibited T cell proliferation in response to high anti-CD3 concen-
trations (500 ng/ml). However, we observed a significant synergy
between abatacept and CsA such that the effect of abatacept was
enhanced by CsA treatment (Fig. 1C). Taken together, these data
demonstrate that although abatacept was effective at limiting the
availability of CD28 costimulation, the requirement for CD28 sig-
naling depended on the strength of TCR engagement.
Abatacept blockade alters the expression of effector molecules
on proliferating T cells
Because T cell proliferation was only weakly suppressed by abatacept
when stimulating with higher anti-CD3 concentrations, we wanted to
determine whether the absence of costimulatory signaling still af-
fected T cells under these conditions. We therefore assessed the
expression of a variety of T cell molecules following activation either
with or without abatacept treatment. Despite the fact that we only
analyzed dividing cells, which by definition are activated, abatacept
markedly reduced expression of the IL-2Ra chain, CD25, as well as
CTLA-4 and ICOS. In contrast, abatacept preventeddownregulation
of PD-1 by T cells that had undergone multiple rounds of division.
Additionally, we observed increased expression of CD28 itself in
the presence of abatacept (Fig. 2). Therefore, although blockade
FIGURE 2. High-dose anti-CD3 promotes abatacept-resistant prolifera-
tion of T cells with an altered phenotype. Activated T cells stimulated for 5 d
with DCs and 500 ng/ml anti-CD36 (20 mg/ml) abatacept were assessed for
the activation markers indicated by flow cytometric analysis. Representative
data (gated only on divided CellTrace Violetlow T cells) are shown as histo-
grams and as mean fluorescence intensity (MFI) values at each CellTrace
Violet division number from eight independent experiments for which data
points represent mean6 SE values. *p # 0.05, **p# 0.01, ***p# 0.001,
two-tailed paired t test. ns, not significant.
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of costimulation did not stop T cell proliferation, abatacept was still
effective in limiting CD28 stimulation and resulted in an alteration
of the phenotype of proliferating T cells.
1,25(OH)2D3 enhances the efficacy of abatacept
Previous studies have identified effects of 1,25(OH)2D3 upon
CD4+ T cell activation and differentiation (24). We therefore
wished to determine whether 1,25(OH)2D3 affected the inhibition
of T cell responses by abatacept. In the presence of DCs, both
abatacept and 1,25(OH)2D3 revealed independent suppressive effects
on T cell proliferation. However, T cell stimulation under these con-
ditions revealed more robust suppression of proliferation in the pres-
ence of both abatacept and 1,25(OH)2D3 (Fig. 3A). Moreover,
abatacept did not obviously influence cell death, either in the
presence or absence of 1,25(OH)2D3, as indicated by DiOC6
low
staining cells following 5-d stimulation (Supplemental Fig. 1).
To determine whether 1,25(OH)2D3 was acting upon the DC,
T cell, or both, we stimulated T cells with anti-CD3 in the presence
of fixed CHO cells expressing FcR and CD80. This system provided
costimulation via a fixed artificial APC that could not be influenced
by 1,25(OH)2D3. Interestingly, 1,25(OH)2D3 alone failed to inhibit
T cell proliferation under these conditions of stimulation (Fig. 3B) in
contrast to DC-mediated activation. However, once again we ob-
served a significant interaction between 1,25(OH)2D3 and abatacept,
demonstrating that 1,25(OH)2D3 enhanced the suppression of T
cell proliferation by abatacept even in the absence of live APCs
(Fig. 3B). These data support a T cell–intrinsic mechanismwhereby
1,25(OH)2D3 acts on T cells to enhance the control of responses by
abatacept.
We also investigated the impact of 1,25(OH)2D3 and abatacept
cotreatment on the expression of inflammatory cytokines in the
context of T cell activation, which have previously been found to be
inhibited by 1,25(OH)2D3 (Fig. 3C). Again we found independent
and additive effects of abatacept and 1,25(OH)2D3 in reducing the
frequencies of proliferating T cells that were IFN-g+ and TNF-a+.
The combination of both agents favored the suppression of inflam-
matory cytokines. Interestingly, we observed a slight trend toward
increased IL-17+ T cells when blocking CD28 costimulation, in
keeping with previous observations (25); however, this effect was
lost in the presence of 1,25(OH)2D3. Together, these data suggest
that 1,25(OH)2D3 supplementation enhances the efficacy of abata-
cept treatment affecting both T cell proliferation and inflammatory
cytokine production.
1,25(OH)2D3 supplementation supports a CD28-driven
proregulatory phenotype by activated T cells
To investigate further the influence of 1,25(OH)2D3 on T cell co-
stimulatory pathways, we assessed T cell activation with particular
regard to the interplay between 1,25(OH)2D3 and abatacept in the
expression of markers of T cell regulation. These experiments
revealed that 1,25(OH)2D3 promoted the expression of CD25 and
CTLA-4with an increased proportion of T cells expressing FOXP3
(Fig. 4A). However, the increased expression of these molecules
FIGURE 3. 1,25(OH)2D3 increases the suppression of T cell proliferation
by abatacept in a T cell–intrinsic manner. CellTrace Violet–labeled CD4+
CD252were incubated with 500 ng/ml anti-CD3 and allogeneic DCs (A) or
CHO-FcR/CD80 (B), with or without 20 mg/ml abatacept and 10 nM
1,25(OH)2D3 for 5 d. Flow cytometric data showing CellTrace Violet dilu-
tion from a representative experiment and combined data from independent
experiments expressed as either division index values or total numbers of
proliferating (CellTrace Violetlow) T cells. Horizontal bars represent mean
values. (C) T cells were stimulated with anti-CD3 and DCs for 5 d, and
the expression of indicated inflammatory cytokines was assessed by flow
cytometry. Data from independent experiments (n = 5); horizontal bars
represent mean values. *p # 0.05, **p # 0.01, ***p # 0.001, paired two-
tailed t test. ns, not significant.
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was CD28 dependent because in the presence of abatacept this
upregulation failed to occur. Interestingly, the expression of CD28
itself was significantly higher in the presence of 1,25(OH)2D3,
suggesting that supplementation promotes CD28 engagement
(Fig. 4B). These data provide evidence that 1,25(OH)2D3 may
actively increase CD28 costimulation, thereby facilitating the
generation of a CD28-driven proregulatory phenotype among ac-
tivated T cells.
1,25(OH)2D3 suppresses anti-CD3– but not anti-CD28–driven
T cell activation
Because T cell proliferation in the presence of abatacept occurred in
the context of high-intensity anti-CD3 signaling, but was rendered
abatacept sensitive by 1,25(OH)2D3, we wished to further explore
the hypothesis that 1,25(OH)2D3 targets the TCR/CD3 pathway,
thereby making T cell proliferation more CD28 dependent. To
compare the TCR/CD3 and CD28 pathways directly, we acti-
vated T cells using anti-CD3 or anti-CD28 cross-linked by FcR-
transfected CHO cells. In this system, both pathways can promote
T cell activation, as evidenced by proliferation at 5 d, with anti-
CD28 possibly behaving in a similar manner to CD28 super-
agonists (Fig. 5A). Although fewer T cells committed to cell di-
vision in response to anti-CD28 compared with anti-CD3, those
T cells that entered the cell cycle underwent an equivalent number
of divisions after 5 d of stimulation and, interestingly, continued to
proliferate for longer than anti-CD3–stimulated T cells (data not
shown). We then compared the sensitivity of anti-CD3 and anti-
CD28 stimulations to CsA. As expected, given the reliance of
TCR signaling on the calcineurin/NFAT pathway, CsA potently
inhibited proliferation of anti-CD3–treated cells, whereas anti-
CD28–stimulated T cells were less affected by CsA (Fig. 5B),
indicative of differences between anti-CD3 and anti-CD28 stim-
ulation. Analysis of T cell activation markers also revealed dif-
ferences between anti-CD3– and anti-CD28–stimulated T cells.
Specifically, ICOS, OX40, and transferrin receptor (CD71) up-
regulation, and CD62L downregulation, were all more strongly
induced by CD28 stimulation. In addition, CD28 stimulation was
associated with increased CD25 expression and enhanced phos-
phorylation of STAT5 (Fig. 5C) and was accompanied by in-
creased FOXP3 and CTLA-4 compared with anti-CD3 stimulation
(Fig. 5D). Together, these data show that anti-CD3 and anti-CD28
promote distinct outcomes.
We next compared the impact of 1,25(OH)2D3 on T cell re-
sponses triggered via either the CD3 or the CD28 pathway. In this
study, we observed that 1,25(OH)2D3 markedly reduced the pro-
liferation of T cells stimulated by anti-CD3, but did not affect
T cells stimulated by anti-CD28 (Fig. 5E). Taken together, these
data show that 1,25(OH)2D3 treatment predominantly targets
T cells stimulated via the CD3 pathway compared with the CD28
pathway.
1,25(OH)2D3 promotes suppression of superantigen-driven
T cell activation by abatacept
Having observed that 1,25(OH)2D3 inhibited anti-CD3–driven
T cell activation, we wanted to determine its impact upon abatacept
sensitivity using an alternative stimulus to anti-CD3 cross-linking.
FIGURE 4. 1,25(OH)2D3 supplementation promotes a Treg phenotype. (A) T cells were stimulated with anti-CD3 and DCs in the presence of 20 mg/ml
abatacept, 10 nM 1,25(OH)2D3, or both for 5 d. After 4-d stimulation, T cells were fixed, permeabilized, and stained for CD25, CTLA-4, and FOXP3. Flow
cytometry data showing FOXP3 against CTLA-4 and CD25 expression and data for CD25, CTLA-4, and FOXP3 from individual experiments (n = 8). Horizontal
bars represent mean values. (B) T cells stimulated in the presence or absence of 10 nM 1,25(OH)2D3 were assessed for CD28 expression after 5 d by flow
cytometry. Representative flow cytometry data and combined data from independent experiments (n = 6). *p# 0.05, **p# 0.01, ***p# 0.001, paired two-
tailed t test.
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We therefore activated T cells with the staphylococcal super-
antigen TSST-1 that facilitates simultaneous interaction between
TCRs that contain the variable b 2-domain (vb2) and MHC II
molecules (26). This allowed us to determine abatacept sensitivity
in the context of a different stimulus in which TCR strength could
be controlled. In this study, at high TSST-1 concentrations, we
noted proliferation of both high-affinity (Vb2+) T cells and low-
affinity (Vb22) T cells (Fig. 6; 0.25 ng/ml TSST-1). However, the
proliferation of low-affinity Vb22 T cells was more abatacept
sensitive, suggesting that CD28 costimulation compensates for
suboptimal TCR stimulation. In comparison, high-affinity Vb2+
responder T cells remained more abatacept resistant, only be-
coming more susceptible to abatacept at lower TSST-1 concen-
trations (Fig. 6A; 0.0025 ng/ml TSST-1). Therefore, the interaction
between abatacept and 1,25(OH)2D3 was more pronounced with
reducing concentrations of TSST-1 (Fig. 6B). These data are
therefore consistent with the concept that 1,25(OH)2D3 targets
TCR-driven proliferation. Thus, using two independent systems
(anti-CD3 and TSST-1), we conclude that 1,25(OH)2D3 targets
TCR-driven activation, increasing CD28 dependence and thereby
promoting the efficacy of abatacept.
Discussion
As the predominant source of T cell costimulation, CD28 signaling
enhances the generation of T cell effector populations via effects upon
proliferation, survival, and differentiation (27). Blocking this signal
FIGURE 5. 1,25(OH)2D3 suppresses TCR but not CD28-induced T cell proliferation. CellTrace Violet–labeled CD4
+CD252 T cells were stimulated with
either 500 ng/ml anti-CD3 or anti-CD28 cross-linked by a FcR-expressing CHO cell (CHO-FcR). (A) Characteristic division at 5 d is indicated by CellTrace
Violet dilution. Numbers indicate the percentage of divided (CellTrace Violetlow) and undivided (CellTrace Violethigh) cells. (B) Stimulations from (A) were
treated with indicated CsA concentrations. Bar charts show the division index values at each concentration plotted as a percentage of the division index for the
untreated control from independent experiments (n = 3). (C) Expression of ICOS, CD71, OX40, and CD62L by dividing T cells was measured by immuno-
fluorescence labeling and flow cytometric analysis. Representative histograms gated on CellTrace Violetlow T cells from n . 3 experiments are shown. (D)
CTLA-4 and FOXP3 expression following anti-CD3 or anti-CD28 treatment was determined by intracellular staining after 4 d. Representative flow cytometry
data and values from independent experiments (n = 5). (E) CD4+CD252 CellTrace Violet–labeled T cells were stimulated with anti-CD3 or anti-CD28 with
or without 10 nM 1,25(OH)2D3. Representative CellTrace Violet histograms showing the impact of 10 nM 1,25(OH)2D3 on anti-CD3– and anti-CD28–driven
T cell at 5 d and data from multiple independent experiments. *p# 0.05, **p# 0.01, ***p# 0.001, paired two-tailed t test.
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using abatacept is effective for the treatment of several T cell–related
diseases (12). However, responses to treatment are variable and
suboptimal in a large proportion of patients. Therefore, the identi-
fication of factors that influence treatment responses along with the
development of approaches to enhance responsiveness is an im-
portant clinical challenge.
The concept that TCR and CD28 cooperate toward a combined
activation threshold in which CD28 provides quantitative support
to the TCR signal has been previously discussed (28). This view is
supported by a significant degree of overlap between TCR and CD28
signalingmediators (29–31) and a reduced TCR signaling threshold
for T cell activation in the presence of costimulation (3). Further-
more, the gene expression pattern following CD28 engagement
alone is comparable to that induced by TCR signaling (32–34). In
this study, we found that abatacept could efficiently inhibit DC-
driven T cell stimulations at low concentrations of TCR stimulus
(anti-CD3 or TSST-1); however, its efficacy diminished as the dose
of the TCR stimulus increased. Indeed, several studies with CD28-
knockout (KO) mice suggest that T cell–mediated immune re-
sponses can occur in a CD28-deficient environment. For example,
T cell responses to lymphocytic choriomeningitis virus, widely
regarded as a strong antigenic stimulus, were normal in CD28-KO
mice (35). Furthermore, CD28-KO T cells could mediate skin al-
lograft rejection (36), acute lethal graft-versus-host disease (37),
and diabetogenic responses in NOD mice (14). The demonstration
that situations exist in which the requirement for CD28 costimu-
lation is overcome could explain the lack of response to abatacept
in some patients.
Our findings are consistent with the concept of CD28 acting as
a quantitative support to the TCR signal and suggest that, under
conditions of sufficient TCR stimulation, T cell responses can occur
in the absence of CD28 costimulation. Conversely, sufficient CD28
costimulation may compensate for a very weak TCR signal to
promote T cell activation. In this respect, we observed T cell
proliferation in response to CD28 engagement in the absence of
overt TCR stimulation. These responses were mediated by FcR-
mediated cross-linking of anti-CD28, but did not occur in re-
sponse to soluble Ab. These CD28-driven responses may occur due to
the formation of tight contacts between T cell and CHO-FcR that
facilitate the size-dependent exclusion of CD45 from the T cell–
CHO-FcR interface as predicted by the kinetic segregation model
(38). This would be analogous to T cell activation driven by CD28
superagonists (39, 40), which generate tight interfaces by binding
to the membrane-proximal C”D loop of CD28 (41). Interestingly,
CD28 superagonists have been found to expand Treg populations
in various model systems (42) consistent with our observations of
a proregulatory phenotype driven by CD28 costimulation. Thus,
signaling via CD28 in isolation allowed us to compare TCR- and
CD28-driven signals and determine that the CD28 pathway is less
sensitive to 1,25(OH2)D3.
We used a number of strategies to selectively reduce the strength of
the TCR signal. The calcineurin inhibitor, CsA, has been regarded as
a TCR-pathway selective inhibitor, whereas CD28 costimulation
promotes CsA-insensitive T cell responses (43). When used at low
concentration, CsA, like abatacept, failed to inhibit T cell prolifer-
ation; however, we found that a combination of CsA and abatacept
was highly effective at inhibiting activation. Other groups have also
demonstrated synergy between CsA and either anti-CD80/CD86
blocking Abs or CTLA-4-Ig for the inhibition of alloresponses
in in vitro MLRs and organ transplantation models (44–47). Thus,
CsA may serve to improve clinical responses to abatacept therapy.
However, there are considerable adverse effects of calcineurin in-
hibition that limit this option (48); hence, alternative TCR-specific
inhibitors are of interest. In this study,we have identified a novel role
FIGURE 6. 1,25(OH)2D3 promotes suppression of T cell proliferation by abatacept in superantigen stimulations. CellTrace Violet–labeled CD4
+CD252
were incubated with indicated TSST-1 concentrations and allogeneic DCs and with either 20 mg/ml abatacept, 10 nM 1,25(OH)2D3, or both for 5 d. (A) Flow
cytometric data showing CellTrace Violet dilution and vb2 staining from one representative experiment. (B) CD4+vb2+ T cell counts were determined relative
to a known quantity of beads added to each sample prior to flow cytometric analysis. Horizontal bars represent mean values from independent experiments (n = 7).
*p# 0.05, **p# 0.01, paired two-tailed t test.
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for 1,25(OH)2D3 as an inhibitor of TCR- but not CD28-driven T cell
responses. Importantly, like CsA, 1,25(OH)2D3 was able to enhance
the efficacy of abatacept in the blockade of anti-CD3– and DC-
driven T cell stimulations.
Vitamin D has diverse immunomodulatory properties, influ-
encing both innate and adaptive immunity. Because both APCs
and T cells express the vitamin D receptor, effects of 1,25(OH)2D3
on T cell responses may occur through either a direct effect on
the T cell or an indirect effect via the APC (24). By using an ar-
tificial fixed CHO system to stimulate T cells, we confirmed that
1,25(OH)2D3 can inhibit TCR-induced proliferation and promote
abatacept sensitivity via a direct effect on the T cell. Our finding
that 1,25(OH)2D3 can inhibit T cell proliferation is consistent
with reports that have demonstrated vitamin D–mediated inhi-
bition of cell cycle progression in various cell lineages, particu-
larly at the G1/S phase transition (49). However, mixed findings
are reported for the effect of vitamin D upon T cell proliferation.
For example, whereas vitamin D has been found to inhibit T cell
proliferation driven byPHA (50–52) invitro, this did not occurwhen
T cells were also costimulated with anti-CD28 (52). Our iden-
tification that 1,25(OH)2D3 acts primarily on TCR-mediated
activation could explain the discrepancy, wherein, the greater
the TCR dependency of the stimulation, the greater the effect of
1,25(OH)2D3.
In addition to influencing T cell activation, vitamin D has been
widely reported to modify T cell effector function, for example,
by inhibiting proinflammatory cytokine production by Th1, Th9,
and Th17 cells (21, 53–56) and biasing differentiation toward
Th2 responses (57). Notably, vitamin D also promotes a regulatory
phenotype characterized by increased expression of FOXP3 and
CTLA-4 (55). Interestingly, Th1 (58)- andTh17 (25)-type responses
are favored by TCR signaling, whereas CD28 signaling favors Th2
(58) and Treg (59). Consistent with these findings, we observed that
abatacept blocked the induction of regulatory markers, including
FOXP3 and CTLA-4, even under conditions in which it was not
effective at suppressing proliferation. This highlights the inherent
tension between inhibiting effector responses and at the same time
influencing regulatory outcomes (60). The fact that vitamin D pro-
motes a regulatory outcome and suppresses inflammatory cytokine
production favors its use in combination therapy; nonetheless, its
ability to induce regulatory markers on activated T cells was still
reduced by abatacept. The fact that the two agents combined to more
potently inhibit T cell proliferation is likely to be beneficial. Im-
portantly, 1,25(OH)2D3 continued to suppress inflammatory cyto-
kine expression even in the presence of abatacept. Thus, greater
inhibition of T cell proliferation as well as the reduction of inflam-
matory cytokines due to the presence of 1,25(OH)2D3 favors its
combination with abatacept as a potential treatment of inflammatory
diseases.
Overall, our data suggest that suboptimal responses to abatacept
treatment could be associated with the strength of the TCR stimulus
that drives the T cell response. Factors that may influence the
strength of the TCR signal between different disease-affected
individuals include autoimmunity-associated genetic variations
(for example, PTPN22, a protein tyrosine phosphatase that reg-
ulates TCR signal transduction) (61) and the antigenic trigger(s).
To enhance responses to abatacept in those in whom pathology is
associated with a strong TCR stimulus, the TCR pathway could be
targeted in addition to the CD28 stimulatory pathway. Our data
demonstrate that, in cases in which abatacept-resistant T cell ac-
tivation occurs due to strong TCR stimulus strength, vitamin D3
supplementation can enhance the efficacy of treatment by inhib-
iting TCR-driven T cell proliferation.
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